Appeal 2007-2516
Application 10/302,553
11. Alliance teaches “porous perforated particles for the delivery of
bioactive agents to the respiratory tract of a patient” (Answer 4). See
Alliance, p. 1.
12. The particles can comprise one or more surfactants (Alliance, p. 10, ll.
18-19), including lipids (such as phospholipids (Alliance, pp. 10, ll. 26 to 11,
l. 1.
13. Surfactants “may further increase dispersion stability, powder
flowability, simplify formulation procedures or increase efficiency of
delivery” (Alliance, p. 10, ll. 20-22).
14. “Generally compatible lipids [surfactants] comprise those that have a gel
to liquid crystal phase transition greater than about 40ºC” (Alliance, p. 11, ll.
3-4).
15. Exemplary phospholipids include dipalmitoylphosphatidylcholine and
disteroylphosphatidylcholine (Alliance, p. 11, l. 6).
16. Alliance’s compositions “typically yield powders with bulk densities
less than 0.5 gm/cm3” (Alliance, p. 9, ll. 24-25).
17. Alliance teaches that “the mean aerodynamic diameter of the perforated
microstructures is preferably less than about 5 µm” (Alliance, p. 29, ll. 3-4).
18. The particles can be administered as an aerosol (Alliance, p. 14, ll. 10-
11).
Clements
19. Clements describes administration of lung surfactant compositions to
treat respiratory distress syndrome (Clements, cols. 1-2: Answer 8).
20. A natural and synthetic lung surfactant was administered to fetal rabbits
to determine the effect on lung function (Clements, cols. 8-10 (“Example
III)).
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: September 9, 2013